Qure Biotechnology
QureBio is a biopharmaceutical company specializing in the development of bispecific and multispecific antibody and protein therapeutics. They focus on addressing unmet medical needs in cancer, autoimmune diseases, and inflammatory disorders through proprietary technology platforms and a robust pipeline of novel drug candidates. Their lead product, Q-1802 (Claudin18.2/PD-L1 bispecific antibody), has received regulatory clearance to initiate clinical trials.
Funding Round: Series C1
Funding Amount: $14M
Date: 05-Jun-2025
Investors: Efung Capital
Markets: Biotech, Therapeutics, Oncology, Immunology
HQ: Shanghai, China
Founded: 2017
Website: http://www.qurebio.com/index.php?m=list&a=index&classid=36
Leave a Comment
Comments
No comments yet.